BMY-14802
BMY-14802, also known as BMS-181100, is a drug with antipsychotic effects which acts as both a sigma receptor antagonist and a 5-HT1A receptor agonist. It also has affinity for the 5-HT2 and D4 receptors. The drug reached phase III clinical trials for the treatment of psychosis but was never marketed.
